Pharmaceutical Technology, Aug 1, 2014 - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Pharmaceutical Technology, Aug 1, 2014
Positive Outlook for Outsourcing
By Jim Miller
Contract services ride high as funding floods bio/pharma.
Featured Content
Shifting Gears in Drug Development Outsourcing Responsibilities
By Rita Peters
For a bio/pharma industry in flux, contract services are playing a greater—and more diverse—role in drug development.
Quality by Design in Contract Service Relationships
Contract service providers describe how quality by design has influenced a drug sponsor's expectations of suppliers.
Analytical Labs Strive to Deliver More Information, Faster
Experts from contract testing laboratories and service organizations shared their perceptions of analytical testing advances, and challenges still ahead.
Technologies Key for Biologics to Meet Expectations
Representatives of contract service organizations that develop biologic-based drugs discussed technology trends such as high-throughput screening and single-use systems.
Solid-Dosage Forms Demand Traditional and Emerging Technologies
Contract development and manufacturing organizations identify trends, challenges, and emerging technology and service needs for solid and semi-solid dosage forms.
CMOs Target Parenteral Drug Development Needs Both Large and Small
Representatives of contract service organizations that specialize in parenteral drug development and manufacturing describe the evolving trends.
Contractors Invest in Capacity and Capabilities
Contract research, development, and manufacturing organizations invested in new facilities and technologies in 2014 for analytical testing, as well as small- and large-molecule drug development.
Weighing Clinical Trial Outsourcing Options
By Bryan Haas , Dave Agrella , Scott Maisto
Evolving clinical trial research services give biopharmaceutical companies options for full and functional services.
Europe's Need for Early Development Pharmaceutical Manufacturing Expertise
By Jon Sutch
Despite the growth of specialist companies with capabilities across various therapeutic areas in Europe, there is still a need for early development expertise with end-to-end pharmaceutical manufacturing capabilities.


LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
Click here